View in EDS HTML Full Text PDF Full Text

A phase I study of HER1, HER2 dual kinase inhibitor lapatinib plus the proteasome inhibitor bortezomib in patients with advanced malignancies.

Saved in:
Bibliographic Details
Title: A phase I study of HER1, HER2 dual kinase inhibitor lapatinib plus the proteasome inhibitor bortezomib in patients with advanced malignancies.
Authors: Lynce, Filipa1,2 (AUTHOR), Wang, Hongkun3 (AUTHOR), Petricoin, Emanuel F.4 (AUTHOR), Pohlmann, Paula R.1,2 (AUTHOR), Smaglo, Brandon5 (AUTHOR), Hwang, Jimmy6 (AUTHOR), He, Aiwu R.1,2 (AUTHOR), Subramaniam, Deepa S.1,2,7 (AUTHOR), Deeken, John8 (AUTHOR), Marshall, John1,2 (AUTHOR), Pishvaian, Michael J.1,2 (AUTHOR) pishvaim@georgetown.edu
Source: Cancer Chemotherapy & Pharmacology. Nov2019, Vol. 84 Issue 5, p1145-1151. 7p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:03445704
DOI:10.1007/s00280-019-03947-7